Home > NEI/FDA CDER Glaucoma Clinical Drug Trial Design and Endpoints Symposium

NEI/FDA CDER Glaucoma Clinical Drug Trial Design and Endpoints Symposium

Archived Page

The information on this page is archived and provided for reference purposes only. It was current when it was produced, but may now be out-of-date. Persons having difficulty accessing this information may contact kcl@nei.nih.gov for assistance. For reliable, current information on this and other topics, we recommend that you visit the National Eye Institute website index.

News Brief
03/13/08

Natcher Auditorium
National Institutes of Health
Bethesda, Maryland
March 13-14, 2008

The National Eye Institute (NEI) and the Food and Drug Administration (FDA) are sponsoring a symposium to consider new disease-relevant outcome measures appropriate for evaluating glaucoma therapies.

For additional information and to register for the symposium, please visit the Association for Research
in Vision and Ophthalmology (ARVO) website at http://www.arvo.org/endpoints.